Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles

Nanomedicine

Volumn 5, Issue 5, 2010, Pages 693-701

  Xie, Shuyu ^a   Pan, Baoliang ^a   Wang, Ming ^a   Zhu, Luyan ^a   Wang, Fenghua ^a   Dong, Zhao ^a   Wang, Xiaofang ^a   Zhou, Wenzhong ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

bioavailability; pharmacokinetics; praziquantel; solid lipid nanoparticles; systemic circulation

Indexed keywords

HYDROGENATED CASTOR OIL; NANOPARTICLE; PRAZIQUANTEL; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CHRONOLOGY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; HEATING; HOT HOMOGENIZATION; IN VITRO STUDY; MALE; MEAN RESIDENCE TIME; MICROSCOPY; MOUSE; NANOENCAPSULATION; NONHUMAN; PHARMACEUTICAL ENGINEERING; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; SYSTEMIC CIRCULATION; ULTRASOUND;

ANIMALS; ANTHELMINTICS; BIOLOGICAL AVAILABILITY; CASTOR OIL; DRUG CARRIERS; LIPIDS; MALE; MICE; NANOPARTICLES; PRAZIQUANTEL;

EID: 77954939796     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.42     Document Type: Article

References (50)

1. Chitsulo L, Engels D, Montresor A, Savioli L: The global status of schistosomiasis and its control. Acta Trop. 77, 41-51 (2000).
2. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J: Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis. 6, 411-425 (2006).
3. Caffrey CR: Chemotherapy of schistosomiasis: present and future. Curr. Opin. Chem. Biol. 11, 433-439 (2007).
4. Meier H, Blaschke G: Investigation of praziquantel metabolism in isolated rat hepatocytes. J. Pharm. Biomed. Anal. 26, 409-415 (2001).
5. Harder A: Chemotherapeutic approaches to schistosomes: current knowledge and outlook. Parasitol. Res. 88, 395-397 (2002).
6. Zhou XN, Chen MG, Mcmanus D, Bergquist R: Schistosomiasis control in the 21st century: proceedings of the International Symposium on Schistosomiasis, Shanghai, July 4-6, 2001. Acta Trop. 82, 95-114 (2002).
7. Chen MG: Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. Acta Trop. 96, 168-176 (2005).
8. Akbarieh M, Besner JG, Galal A, Tawafhail R: Liposomal system for the targeting and controlled release of praziquantel. Drug Dev. Ind. Pharm. 18, 303-307 (1992).
9. El-Arini, SK, Leuenberger H: Dissolution properties of praziquantel - PVP systems. Pharm. Acta Helv. 73, 89-94 (1998).
10. Danso-Appiah A, De Vlas SJ: Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol. 18, 125-129 (2002).
11. Doenhoff MJ, Kusel JR, Coles GC, Cioli D: Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans. R. Soc. Trop. Med. Hyg. 96, 465-469 (2002).
12. Cioli D: Praziquantel: is there real resistance and are there alternatives? Curr. Opin. Infect. Dis. 13, 659-663 (2000).
13. Xiao SH, Catto BA, Webster LT: Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J. Infect. Dis. 151, 1130-1137 (1985).
14. Andrews PA: Summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action. Arzneimittelforschung31(3a), 538-541 (1981).
15. Mainardes RM, Evangelista RC: PLGA nanoparticles containing praziquantel : effect of formulation variables on size distribution. Int. J. Pharm. 290, 137-144 (2005).
16. Jung H, Medina R, Castro N, Corona T, Sotelo J: Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob. Agents Chemother. 41, 1256-1259 (1997).
17. Castro N, Jung H, Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J: Interaction between grapefruit juice and praziquantel in humans. Antimicrob. Agents Chemother. 46, 1614-1616 (2002).
18. Metwally AA, Bennett JL, Botros SS, Ebeid FA: Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel. Drug Res. 45(4), 516-518 (1995).
19. Castro N, Medina R, Sotelo J, Jung H: Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob. Agents Chemother. 44, 2903-2904 (2000).
20. Becket G, Schep LJ, Tan MY: Improvement of the in vitro dissolution of praziquantel by complexation with a-, p- and g-cyclodextrins. Int. J. Pharm. 179, 65-71 (1999).
21. De Jesus MB, De Matos Alves Pinto L, Fraceto LF et al.: Theoretical and experimental study of a praziquantel and p-cyclodextrin inclusion complex using molecular mechanic calculations and H1-nuclear magnetic resonance. J. Pharm. Biomed. Anal. 41, 1428-1432 (2006).
22. Bayomi MA, Al-Suwayeh SA, El-Helw AM, Mesnad AF: Preparation of casein-chitosan microspheres containing diltiazem hydrochloride by an aqueous coacervation technique. Pharm. Acta Helv. 73, 187-192 (1998).
23. Mourao SC, Costa PI, Salgado HR, Gremiao MP: Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine- containing liposomes. Int. J. Pharm. 295, 157-162 (2005).
24. Gonnert R, Andrews P: Praziquantel, a new board-spectrum antischistosomal agent. Z. Parasitenkd. 52, 129-150 (1977).
25. Webbe G, James C: A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum and S. mattheei in hamsters. Z. Parasitenkd. 52, 169-177 (1977).
26. Dayan AD: Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop. 86, 141-159 (2003).
27. Xie SY, Wang SL, Zhao BK etal.: Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Colloids Surf. B Biointerfaces 67, 199-204 (2008).
28. Han C, Qi CM, Zhao BK et al.: Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J. Vet. Pharmacol. Ther. 32, 116-123 (2009).
29. Wang SL, Xie SY, Zhu LY, Wang FH, Zhou WZ: Effects of poly (lactic-co-glycolic acid) as a co-emulsifier on the preparation and hypoglycaemic activity of insulin-loaded solid lipid nanoparticles. IETNanobiotechnol. 4, 103-108 (2009).
30. Duchene D, Ponchel G: Bioadhesion of solid oral dosage forms, why and how? Eur. J. Pharm. Biopharm.44(1):15-23(1997)
31. Luo Y, Chen D, Ren L, Zhao X, Qin J: Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J. Control. Release 114, 53-59 (2006).
32. Li SY, Zhao BK, Wang FH et al.: Yak interferon-a loaded solid lipid nanoparticles for controlled release. Res. Vet. Sci. 88(1), 148-153 (2009).
33. Pica-Mattoccia L, Cioli D: Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int. J. Parasitol. 34, 527-533 (2004).
34. Cioli D, Pica-Mattoccia L: Praziquantel. Parasitol. Res. 90(Suppl. 1), S3-S9 (2003).
35. DeMerlis CC, Schoneker DR: Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem. Toxicol. 41, 319-326 (2003).
36. Sahoo SK, Panyam J, Prabha S, Labhasetwar V: Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release 82, 105-114 (2002).
37. Zambaux MF, Bonneaux F, Ref RG et al.: Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J. Control. Release 50, 31-40 (1998).
38. Xie SY, Wang SL, Zhu LY, Wang FH, Zhou WZ: The effect of glycolic acid monomer ratio on the emulsifying activity of PLGA in preparation of protein-loaded SLN. Colloids Surf.AB Biointerfaces 74:358-361(2009)
39. Hu L, Tang X, Cui F: Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J. Pharm. Pharmacol.,56:1527-1535(2004)
40. Holm R, Mullertz A, Christensen E, Hoy CE, Kristensen HG: Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur. J. Pharm. Sci. 14, 331-337 (2001).
41. Rieux AD, Fievez V, Garinot M, Schneider YJ, Preat V: Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116, 1-27 (2006).
42. Hussain N, Jaitley V, Florence AT: Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 50, 107-142 (2001).
43. Wasan KM: Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Dev. Ind. Pharm. 27, 267-276 (2001).
44. Barratt G: Colloidal drug carriers: achievements and perspectives. CellMol. Life Sci. 60, 21-37 (2003).
45. Kipp JE: The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 284, 109-122 (2004).
46. Muller, RH, Mader K, Gohla S: Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161-177 (2000).
47. Wissing SA, Kayser O, Muller RH: Solid lipid nanoparticles for parenteral drug delivery. Adv. DrugDeliv. Rev. 56, 1257-1272 (2004).
48. McLennan DN, Porter CJ, Charman SA: Subcutaneous drug delivery and the role of the lymphatics. Drug Discov. Today Technol. 2(1), 89-96 (2005).
49. Baert L, Klooster GV, Dries W et al.: Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72 (3), 502-508 (2009).
50. Xiao SH, You JQ, Mei JY, Jiao PY: Early treatment of schistosomal infection with praziquantel in mice. Acta Trop. 14, 533-538 (1993).